News ‘Trojan horse’ cancer drug shows promise in multiple tumour ... A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
News Seattle Genetics and Astellas gain Breakthrough Designation ... The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
Partner Content Partner Content Exclusive Speaker Interview from Seattle Genetics for SMi’s ... Interview from Seattle Genetics
News Seattle, Takeda aim for first line Adcetris use Seattle CEO hopes Adcetris will be standard of care.
News Seattle Genetics halts trials of latest ADC after safety war... Monitoring committee concerned about high death rates.
News Seattle Genetics leukaemia trial on hold after 4 deaths FDA concerned over potential liver toxicity.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends